comparemela.com
  1. Home
  2. Live Updates
  3. About Luveltamab - Breaking News

About Luveltamab News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023

– Complete remission seen in 42% of patients with CBF/GLIS AML with ≥5% blasts and 75% of pediatric patients with CBF/GLIS AML with .

United statesSan diegoSouth san franciscoLuveltamab tazevibulinSoheil meshinchiSutro biopharmaEmily whiteGlobenewswire incExchange commissionAmerican society of hematology annual meetingDrug administrationSutro biopharma incHematology annual meetingAbout luveltamabFast trackOvarian cancer

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.